Sacituzumab Tirumotecan for Advanced Pancreatic Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called sacituzumab tirumotecan for pancreatic cancer that has progressed despite prior treatment. The drug is designed to target cancer cells and deliver chemotherapy directly to them, potentially working better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Pancreatic cancer confirmed by biopsy or cell sample that has grown despite at least one prior chemotherapy treatment
- At least one measurable tumor on imaging that has not been previously treated with radiation (or showed growth after radiation)
- Able to perform daily activities with minimal limitations (ECOG score 0–2)
- Healthy enough organ and blood counts to safely receive the drug
- No cancer spread to the brain or unstable spinal cord compression
- No prior treatment with TROP2-targeted drugs or similar antibody-drug conjugate therapies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests a new drug, sacituzumab tirumotecan, in people with squamous cell carcinoma of the anus or rectum that has spread or cannot be removed. It aims to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new cancer drug called sacituzumab tirumotecan (a targeted antibody-drug) in patients with adenoid cystic carcinoma or papillary thyroid cancer that has spread or cannot be surgically removed. The drug is designed to find and attack cancer cells while minimizing harm to healthy cells.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced biliary tract cancer that has stopped responding to previous treatments. It works by targeting a protein called TROP2 on cancer cells. This may be an option if your cancer has progressed and you meet the health criteria.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.